SCHEMBL19366291

SCHEMBL19366291

CCC1CCc2cc(OC(=S)n3ccnc3)c(OC)cc2C1C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.33
KMT2A Q03164 6/20 0.33
HIF1A Q16665 4/20 0.33
LMNA P02545 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
CYP3A4 P08684 3/20 0.33
MAPK1 P28482 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
MAPT P10636 2/20 0.33
STAT6 P42226 2/20 0.33
EPAS1 Q99814 2/20 0.33
SLC2A1 P11166 2/20 0.33
TP53 P04637 1/20 0.33
NFKB1 P19838 1/20 0.33
THPO P40225 1/20 0.33
HTT P42858 1/20 0.33
RBBP9 O75884 1/20 0.33
ABCB1 P08183 1/20 0.33
HTR1A P08908 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17531505 0.85 SLC18A2 (0.32) MEN1KMT2ASMN1; SMN2
SCHEMBL17538348 0.81 MAOA (0.36) SMN1; SMN2MAPTHTTKDM4EALDH1A1
SCHEMBL19366285 0.77 MAOA (0.33) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL19366289 0.75 HSD17B2 (0.36)
SCHEMBL17531504 0.74 SLC18A2 (0.34) MEN1KMT2ASMN1; SMN2MAPK1KDM4E
SCHEMBL19067937 0.73 PLK1 (0.40) PDE4D
SCHEMBL19067935 0.71 KMT2A (0.39) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL19067934 0.70 HSD17B10 (0.44) LMNAMAPK1KDM4EALDH1A1HPGD
SCHEMBL17538347 0.69 SMN1; SMN2 (0.40) MEN1KMT2ASMN1; SMN2MAPK1NPC1
SCHEMBL19366294 0.69 KMT2A (0.41) MEN1KMT2ALMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 MEN1 1546/4885KMT2A 3574/4885HIF1A 3171/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 MEN1 1546/4885KMT2A 3574/4885HIF1A 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.